CollaGenex Pharmaceuticals have just announced phase II clinical trial data showed its experimental acne treatment was indeed successful in controlling acne.
During the study in which over 300 patients took part, CollaGenex discovered that the minimum effective dose of its acne treatment incyclinide was 10 mg, but that a 20 mg dose was more effective. Incyclinide was also found to have a similar side effect profile to placebo.
Although the company claim the study was not powered for statistical significance (the benchmark the FDA uses to determine effectiveness) during the study incyclinide showed a statistically significant clinical benefit when compared to placebo at particular dosages.
After 3 weeks, a 25.9% reduction in acne was found in patients given 20 mg of incyclinide, compared with 9.4% in the placebo group.
Six weeks into the trial, incyclinide patients were found to have a reduction of 36%, compared with a 17.5% reduction in the placebo group.